Novum Pharma, a small drug company that makes specialty skin creams, has hired its first lobbyists in Washington, D.C. — three lawyers at Buchanan Ingersoll & Rooney — who will advocate for undefined "pricing issues affecting the pharmaceutical industry."
Driving the news: Novum's federal lobbying document was signed just two days before Bloomberg published a profile of the company's top two leaders, who have been known to raise drug prices significantly. Michael Strazzela, one of Novum's lobbyists, said the registration had nothing to do with the Bloomberg story, and the company is interested in ways to "fix the broken pricing system."